8. Commitments and Contingencies
Under the terms of the license agreement
under which the Company acquired the rights to its product candidates, in order to retain its rights to the licensed technology
the Company must receive revenues or fund a minimum of $2 million in qualified research, development and commercialization expenses
before March 8, 2014 (at least $0.5 million of which must be before March 8, 2012 and at least $1million before March 8, 2013).
If the Company or a sublicense is successful in commercializing the therapeutic vaccine candidate or diagnostic test, the Company
will be obligated to pay the licensor two percent (2%) of any royalties received if the Company grants any third parties royalty-bearing
licenses to the licensed technology. In addition, the Company has agreed to pay the licensor a royalty of one quarter of one percent
(0.25%) of all gross revenue resulting from use of the technology licensed by the Company. Although the Company did not spend the
$0.5 million additional funds per the Licensing Agreement before March 8, 2012, we have not received a default letter and as of
June 30, 2012, the Company was in negotiations to extend the terms of the Agreement.
On February 27, 2011, the Company entered
into a Consulting Services Agreement with AVP. The agreement requires AVP to provide the Company with certain advisory services
that include reviewing the Companys business plan, identifying and introducing prospective financial and business partners,
and providing general business advice regarding the Companys operations and business strategy. Cash compensation of $400,000
is due upon the Company securing $5 million in available cash from funding, and an additional $400,000 is due upon the Company
securing $10 million in available cash from funding (inclusive of the first $5 million). The cash compensation is to be paid to
AVP at the rate of $66,667 per month. The total cash compensation to be received by AVP is not to exceed $800,000 unless the Company
receives an amount of funding in excess of $10 million. If the Company receives equity or debt financing that is an amount less
than $5 million, in between $5 million and $10 million, or greater than $10 million, the cash compensation earned by the AVP under
its consulting services agreement will be prorated. The Company has the option to make a lump sum payment to AVP in lieu of the
monthly cash payments.
As permitted under Delaware law and
in accordance with its Bylaws, Virolab indemnifies its officers and directors for certain expenses incurred from legal or other
proceedings that arise as a result of the director or officers service to the Company. There is no limitation on the term
of the indemnification and the maximum amount of potential future indemnification is unlimited. The Company currently does not
have a directors and officers insurance policy that could limit its exposure and enable it to recover a portion of any future amounts
paid. The Company believes the fair value of these officer and director indemnification agreements is minimal, and, accordingly,
has not recorded any liabilities for these agreements as of March 31, 2012.
From time to time, Virolab may be involved
in claims and other legal matters arising in the ordinary course of business. Management is not currently aware of any matters
that it believes are likely to have a material adverse effect on its financial position or results of operations.